Low Dose Aspirin Associated with a Lower Risk of Hepatocellular Carcinoma
Results of a study conducted among adults with chronic viral hepatitis in Sweden
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1616 results
EMA Recommends Granting Marketing Authorisation for Generic Azacitidine
Azacitidine betapharm and Azacitidine Mylan are generic of Vidaza, which has been authorised in the EU since 2008
FDA Grants Accelerated Approval to Nivolumab and Ipilimumab Combination for Hepatocellular Carcinoma
Evidence for efficacy is based on the results from the CHECKMATE-040 study
Systematic Viability Profiling of the Anticancer Potential of Non-Oncology Drugs
PRISM repurposing dataset represents nearly half of all drugs ever tested in humans
Use of Both, MRI-Targeted and 12-Core Systematic Biopsies in Prostate Cancer
Combined biopsy more effective in detection of prostate cancer
Withdrawal of Application to Change the Marketing Authorisation for Axumin
Intended extension of the use of fluciclovine (18F) was to include the detection and monitoring of glioma in adults using a PET scan
Withdrawal of Application to Change the EU Marketing Authorisation for Nivolumab and Ipilimumab
Intended extension of indication concerned metastatic non-small cell lung cancer that has not been previously treated
FDA Approves Isatuximab-irfc for Multiple Myeloma
Evidence for efficacy is based on the results from the ICARIA-MM study
EORTC Updates QoL Module in Breast Cancer
New items contain multi-item scales on a target symptom and satisfaction
Breast MRI Associated with a Significantly Higher Rate of Invasive Cancer Detection than Digital Breast Tomosynthesis
Findings form a cross-sectional study with longitudinal follow-up among women with dense breasts undergoing screening
EMA Started a Review of Trabectedin
The review is initiated after an interim analysis of the results from the OVC-3006 study conducted in patients with ovarian cancer
EMA Recommends Extension of Therapeutic Indications for Brigatinib
New indication concerns monotherapy in patients with ALK positive advanced NSCLC previously not treated with an ALK inhibitor